In our previous study we used the linear-quadratic model ͓J. Nucl. Med. 35, 1861 ͑1994͔͒ to confirm our initial finding, based on the time-dose-fractionation model ͓J. Nucl. Med. 34, 1801 ͑1993͔͒, that longer-lived radionuclides ͑e.g.,
INTRODUCTION
The goal in radioimmunotherapy ͑RIT͒ is to deliver therapeutic doses to tumors without compromising the function of the critical organs such as bone marrow. To date, the use of relatively short-lived radionuclides such as 90 Y has resulted in limited therapeutic success for a number of reasons. Among the reasons are: ͑i͒ the absolute uptake of radioactivity per gram of tumor is too low to yield a tumorcidal dose, and ͑ii͒ the uptake of radioactivity in the tumor is nonuniform thereby delivering a nonuniform dose to the tumor. Furthermore, when short-lived radionuclides are used, the effective uptake half-times (T eu,t ϳ1 -2 d) of the radiolabeled antibodies in human tumors are frequently comparable to the effective tumor clearance half-times (T e,t ϳ2 -7 d), while the effective half-times in the body T e,B are ϳ1 -4 d. [1] [2] [3] [4] Under these conditions, much of the radioactivity decays in normal tissues before it has an opportunity to be taken up by the tumor, resulting in relatively high doses to normal tissues and low doses to tumors. Given these general conditions in RIT, it is desirable to increase the effective half-time in the tumor relative to the effective half-time in the critical organs to improve therapeutic efficacy. For a given antibody, the effective half-time of the radiolabeled antibody can in principle be lengthened by increasing the physical half-life of the radionuclide (T p ). Therefore, the physical half-life of the radionuclides should be matched to the biological conditions. Radionuclides irradiate tissues chronically with dose rates that vary exponentially with time. Hence, dose rate effects play a role in the biological outcome. 5, 6 Our recent work which used the time-dose-fractionation ͑TDF͒ and linearquadratic ͑LQ͒ models to account for dose rate effects showed that longer-lived radionuclides can provide a substantial therapeutic advantage in RIT. 7, 8 Our initial approach with the LQ model took into consideration the radiosensitivity of the tissues, repair rates, dose rates, and biological and physical half-lives to obtain biologically effective doses ͑BED͒ delivered to the tumor and bone marrow. 8 The present work builds upon our past modeling by including the proliferation of these tissues and examines the impact of tumor radiosensitivity. Relative advantage factors ͑RAF͒ are calculated for several radionuclides with different physical halflives and compared with the values obtained in our earlier calculations. 7, 8 
THEORETICAL MODELING

Linear-quadratic model
The linear-quadratic model is generally applicable for conventional therapies involving multiple fractions of acute external beams of radiations, as well as brachytherapy at constant dose rates and exponentially decaying dose rates. [9] [10] [11] In this model the fraction of cells surviving a fractionated regimen of acute radiation insults is given by S ϭe ϪE , where 10 EϭND N ͑␣ϩ␤D N ͒. ͑1͒
The quantity N is the number of fractions, D N the dose per fraction, and ␣ and ␤ are the linear and quadratic coefficients of the dose response relationship, respectively. The total dose D delivered during the regimen is N•D N . The biologically effective dose ͑BED͒ has been defined as 10 BEDϭ
where RE is the relative effectiveness per unit dose. 11 For fractionated external beam radiotherapy, the relative effectiveness per unit dose is [9] [10] [11] REϭ1ϩD N ͩ ␤ ␣ ͪ .
͑3͒
For protracted irradiation as a result of the complete decay of permanent implants, Dale 10 has shown that the RE can be written as
where r 0 is the initial dose rate, T p the physical half-life, and T the repair half-time.
In the case of brachytherapy with permanent sealedsource implants, the dose rate to the tumor decreases monoexponentially from some initial value. However, in RIT the dose rate to the tumor rises from an initial value of zero to a maximum value as the radioactivity is taken up by the tumor, and then decreases exponentially as the radioactivity decays and clears from the tumor. Similar dose rate patterns are frequently observed for the critical normal organs as well. The functional form of the dose rate to the critical organ or tumor can typically be represented by
where T d is the dose rate decrease half-time during the clearance phase of the radionuclide from the organ, and T i is the dose rate increase half-time during the uptake phase of the radionuclide by the organ with the provision that T d ϾT i . The quantity r 0 is now the extrapolated initial dose rate. 7, 8, [12] [13] [14] When the dose rate decrease and increase halftimes are well represented by the effective clearance and uptake half-times ͑T e and T eu ͒, the dose rate at time t is given by 8, 12 r͑t ͒ϭr 0 ͑ e Ϫln 2͑t/T e ͒ Ϫe Ϫln 2͑t/T eu ͒ ͒. ͑6͒
The effective clearance half-time T e is given by T p T b /(T p ϩT b ) and the effective uptake half-time T eu is given by T p T u /(T p ϩT u ), where T u and T b are the biological uptake half-time and clearance half-time, respectively. The relative effectiveness per unit dose for incomplete decay of radioactivity with dose rate kinetics specified by Eq. ͑6͒ can be derived by following the steps outlined in Appendix II of Dale. 10 In Appendix II, Dale derives RE for incomplete decay of a radioactive source with r(t) ϭr 0 exp(Ϫt). By substituting Eq. ͑6͒ for r(t)ϭr 0 exp(Ϫt) throughout Dale's 10 derivation, it can be shown that the RE for incomplete decay of radioactivity with dose rate kinetics specified by Eq. ͑6͒ is given by
Ϫe Ϫ͑ϩ e ͒t ͒Ϫ 1 ͑ϩ eu ͒ ͑1Ϫe
where e ϭln 2/T e , eu ϭln 2/T eu , and ϭln 2/T . This expression is valid for either tumor or normal tissue.
Linear-quadratic model with proliferation "LQP model…
As stated earlier, 8 Eqs. ͑2͒ ͑6͒, and ͑7͒ are useful for predicting required extrapolated initial dose rates and total doses in radioimmunotherapy using the LQ model. However, the above formalism does not take into account the proliferation of normal and tumor tissues. [15] [16] [17] Proliferation can play a substantial role in the therapeutic outcome. Dale 15 and Ling 16 have described methods to include a proliferation term in the linear-quadratic model. When proliferation is taken into consideration, the biologically effective dose at any time t can be written as:
where t is the time postinjection of the radioactivity, T rd is the regrowth delay time, and T g is the potential doubling time. For chronic irradiation, the regrowth delay time is the time delay between the beginning of the irradiation and the initiation of the proliferation response. The potential doubling time is the time required for the tissue to double its cell population. Thus Eq. ͑8͒ is essentially the linear-quadratic model with the addition of a proliferation term, henceforth referred to as the LQP model.
Relative advantage factor
It has been shown earlier that when one requires that two different radionuclides deliver the same biologically effec-tive dose to the tumor BED t and the same deleterious biologically effective dose to the bone marrow BED B , the benefit of longer-lived radionuclides can be expressed in terms of the required extrapolated initial dose rates as a relative advantage factor ͑RAF͒
where s denotes short-lived and l denotes longer-lived radionuclide. Hence, the RAF is defined as the factor by which it is more likely to deliver a sterilization dose to the tumor with a longer-lived radionuclide than with a short-lived radionuclide for the same biologically effective dose to the critical organ.
8
Input parameters
To compare the impact of proliferation on the relative advantage of longer-lived radionuclides in radioimmunotherapy, calculations are carried out using the same ''standard'' input parameters used in our previous calculations. 7, 8 Hence, it is assumed that a biologically effective dose to the tumor BED t of 69.3 Gy is required to be delivered. In these calculations, where proliferation is an issue, this corresponds to the maximum BED t achieved which occurs at the nadir of the tumor cell survival curve. This is equivalent to a 226 Ra regimen of 60 Gy over 7 d, or a TDFϭ100. Similarly, the biologically effective dose to the bone marrow BED B is restricted to a value of 3. . These values are in agreement with those of Wu and Lajtha. 18 For cultured human LS174T tumor cells, our preliminary data give T g,t ϭ1.5 d, and the data of Wong et al. 19 give ␣ t ϭ0.56 Gy Ϫ1 and T rd,t ϳ4 d at therapeutic doses. These parameters are given in Table I . While the above parameters represent ''standard'' conditions, calculations are also performed for various values of BED t , ␣ t , and T b,t . 
RESULTS AND DISCUSSION
Relative advantage of longer-lived radionuclides
To compare the relative advantage of several potentially useful radionuclides with different physical half-lives, the RAFs compared to 90 Y are given in Table II for 32 P and 114m In. As stated earlier, these three radionuclides have physical half-lives of 2.7 d, 14.3 d, and 49.5 d, respectively. As in our past analyses, it is required that BED t ϭ69.3 Gy, BED B ϭ3.2 Gy, T ϭ1.5 h, T u,t ϭ1.9 d, T b,t ϭ13.4 d, and T b,B ϭ3.7 d. However, the BEDs are now required to be achieved at the nadir as opposed to the previous requirement of complete decay. 8 The proliferation parameters given in Table I were used in this analysis. The effective uptake and clearance half-times are given in rows 1-3 of Table II for each radionuclide. The calculated values of the extrapolated initial dose rates r 0,B and r 0,t , required to achieve BED t ϭ69.3 Gy, while restricting BED B ϭ3.2 Gy, are given in rows 5 and 7 for each of the radiobiological models ͑time dose fractionation: TDF, 7 linear quadratic: LQ, 8 and linear quadratic with proliferation: LQP͒. The corresponding required total absorbed doses for the bone marrow and tumor are given in rows 6 and 8, respectively. As expected, the required values of r 0,t and r 0,B decrease substantially as the effective clearance half-time of the radiolabeled antibody increases. The ratios r 0,t /r 0,B are given in row 9 of Table II . These ratios indicate that the extrapolated initial dose rate to the tumor must be about 30 times higher than the extrapolated initial dose rate to the marrow to achieve a BED t ϭ69.3 Gy and a marrow sparing BED B ϭ3.2 Gy with 90 Y. In contrast, the tumor dose rate only has to be about 10 times higher than the marrow dose rate in the case of 114m In to achieve the desired BEDs. A ten-fold tumor to nontumor ratio is clearly easier to accomplish than a thirty-fold ratio. Finally, the relative advantage of each radionuclide compared to 90 Y is given in row 10 of In, respectively, even when proliferation is included. Hence, longer-lived radionuclides can be at least three times more likely than 90 Y to succeed in delivering a therapeutic dose to the tumor while maintaining an acceptable level of radiotoxicity to the bone marrow. As predicted in our earlier report, 8 the results clearly show that inclusion of proliferation has little impact on the RAFs. The extrapolated initial dose rates and total doses required, however, are substantially higher for the LQP model than the LQ model. 8 Interestingly, the extrapolated initial dose rates and total doses required by the LQP model are similar to those obtained with the TDF model. 
Dependence of relative advantage factor on T g,t and T rd,t
In the above calculations which examine the effect of proliferation on the relative advantage of longer-lived radionuclides in RIT, it is assumed that the tumor regrowth delay time T rd,t ϭ4 d, tumor potential doubling time T g,t ϭ1.5 d, marrow regrowth delay time T rd,B ϭ8 d, and marrow potential doubling time T g,B ϭ2 d. These assumptions imply that the tumor is proliferating faster than the marrow which is likely when the tumor is very small. When bulk tumors are present, the above proliferation parameters may be unrealistic. To examine the advantage of longer-lived radionuclides for slowly proliferating tumors, the relative advantage factors are calculated assuming T rd,t ϭ8 d, T g,t ϭ4 d, and all other tumor and marrow parameters remaining the same as in Table I Table II͒ . This suggests that longer-lived radionuclides are even more advantageous when the tumor proliferates slowly. However, in bulk tumors, our ability to predict the biological response for a given treatment regimen is complicated by the fact that the radionuclide is likely to be distributed nonuniformly [20] [21] [22] and much of the tumor is poorly oxygenated.
21,22
Dependence of relative advantage factor on ␣ t ,
The RAF values calculated in Table II use parameters for a relatively radiosensitive tumor having (␣/␤) t ϭ10 Gy, and ␣ t ϭ0.56 Gy
Ϫ1
. The dependence of the RAF on radiosensitivity of the tumor can be examined by varying ␣ t accordingly. Figure 1 shows that the RAF does indeed decrease as the tumor becomes more resistant, however, the advantage of longer-lived radionuclides remains substantial even for very resistant tumors. The decrease in the RAF occurs because the proliferation term in the BED expression is inversely proportional to ␣ ͓see Eq. ͑8͔͒ which means that the proliferation term plays a greater role in determining BED for resistant tumors ͑tumors with small ␣͒ than sensitive tumors. In order In ͑solid͒. The value of ␣/␤ is maintained at 10 Gy and the parameters are as given in Table I . A substantial therapeutic advantage is maintained by the use of longer-lived radionuclides even for radioresistant tumors.
to overcome the increased importance of proliferation in resistant tumors, higher extrapolated initial dose rates and total doses are necessary compared to relatively more sensitive tumors. Consequently, the RAF values are somewhat less for resistant tumors.
Dependence of relative advantage factor on BED t
The RAF values presented in Table II assume that a therapeutic dose (BED t ϭ69.3 Gy) can be delivered to the tumor in radioimmunotherapy. When therapeutic doses cannot be realized, the tumor may receive a BED substantially lower than 69.3 Gy. Figure 2 shows the dependence of the relative advantage of longer-lived radionuclides on BED t . It can be seen that when BED t drops to 20 Gy, the advantage of longer-lived radionuclides in RIT is still maintained, albeit to a lesser degree. However, as BED t decreases from 20 Gy to 0 Gy, the RAF drops rapidly to 1. This drop is due to the fact that at low BED t values, a larger portion of the dose delivered is utilized to overcome proliferation of the tumor. These results suggest that even when RIT is used as an adjuvant therapy with BED t values in the range of 20-30 Gy, longerlived radionuclides still offer a substantial advantage over the shorter-lived radionuclides currently in use.
Dependence of relative advantage factor on T b,t
The RAF values obtained in Table II were calculated using the ''standard'' parameters in Table I . The ''standard'' biological half-time in the tumor T b,t is assumed to be 13. 
CONCLUSIONS
The linear-quadratic model, replete with a proliferation term, is used to examine the advantage of longer-lived radionuclides in radioimmunotherapy. The model incorporates differences in dose rates, biological half-times of the antibodies, physical half-lives of the radionuclides, total doses required for a given biological effect in tumor and normal tissues, repair half-times, proliferation and radiation response of the tissues. Cu (T p ϭ59 h) labeled BAT-Lym-1 antibodies in humans shows that the therapeutic index ͑tumor dose/ marrow dose͒ is higher for the longer-lived radionuclide 67 Cu than the shorter-lived radionuclide 64 Cu. This provides experimental evidence of the advantage of longer-lived radionuclides over shorter-lived radionuclides, consistent with the theoretical predictions of the LQ model. Another noteworthy observation is that when proliferation is folded into the LQ model, the predicted extrapolated initial dose rates and total doses are very similar to the values predicted by the empirical TDF model ͑Table II͒. Finally, as shown in our earlier publication, 7 selection of the physical half-life of the radionuclide should be based on the biological uptake and clearance times of the antibody with the optimal physical half-life being about 2-3 times the biological clearance halftime of the antibody in the tumor. Physical half-lives greater than 2-3 times the biological clearance half-time provide little additional gain in the RAF because further increase in the physical half-life has little impact on the effective halftime.
